ViraCyte, LLC announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Viralym-C, ViraCyte's T cell immunotherapy product designed to treat refractory cytomegalovirus (CMV) infections in patients following a stem cell transplant. Fast Track designation is designed to expedite the development and review of new therapies to treat serious conditions for which patients have a significant unmet medical need. Advantages of Fast Track designation include more frequent interactions with the FDA during all aspects of development of the therapy, and eligibility for priority review and accelerated approval.